meRfi®-GM
NCT01853748 - ATEMPT - Trastuzumab emtansine vs Paclitaxel + Trastuzumab & Breast Cancer / Mammacarcinoma (HER2+)
Welcome to meRfi-GM!
meRfi-GM provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
Navigation
Contents
The ATEMPT trial aimed to see if trastuzumab emtansine (T-DM1) had less toxicity than paclitaxel plus trastuzumab (TH). It also checked if it provided acceptable invasive disease-free survival (iDFS) for stage I Breast Cancer / Mammacarcinoma (HER2+) patients.
Primary outcome measures
To compare toxicities between Trastuzumab emtansine and Paclitaxel + Trastuzumab.
Conclusion
For stage I Breast Cancer / Mammacarcinoma (HER2+), one year of Trastuzumab emtansine showed excellent 3-year invasive disease-free survival (iDFS). However, it did not reduce clinically relevant toxicities (CRTs) compared to Paclitaxel + Trastuzumab.
Tolaney et…